Concepedia

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

Greg Moeck, Leanne B. Gasink, Rodrigo E. Mendes, Leah N. Woosley, MaryBeth Dorr, Hongzi Chen, Florian Wagenlehner, Tim Henkel, Paul C. McGovern

Antimicrobial Agents and Chemotherapy · 2024 · 14 citations · 21 references

DOIFull text

Open access

Abstract

This study is registered with ClinicalTrials.gov as NCT03840148.

References

21

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa

Lindsay E. Nicolle, Kalpana Gupta, Suzanne Bradley et al. · Clinical Infectious Diseases · 2019 · 714 citations · Full text

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2023 · 631 citations · Full text

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America

Lindsay E. Nicolle, Kalpana Gupta, Suzanne Bradley et al. · Clinical Infectious Diseases · 2018 · 452 citations · Full text

Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis

Lorenzo Moja · 2017 · 393 citations

, , +14

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 387 citations

, , +10